Gene‑editing heavyweight Metagenomi cut roughly 25% of its workforce — including the CEO — as it refocuses on a preclinical hemophilia A program, the company said in a corporate restructuring announcement. The staffing reduction accompanies a strategic narrowing of priorities to extend runway and concentrate resources on MGX‑001. Separately, Metagenomi published preclinical data showing curative factor VIII (FVIII) activity in non‑human primates for MGX‑001, the hemophilia A candidate designed to deliver durable FVIII expression. The juxtaposition — workforce contraction alongside potent NHP efficacy — highlights the pressures on genome‑editing companies to convert promising preclinical biology into a concrete regulatory and commercial path while managing limited capital and pipeline risk.